Nuvalent, Inc.
$90.18
-1.6%Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -15.4).
Valuation inputs: P/E -15.4, earnings yield N/A, momentum -1.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -34.1%, ROIC -31.4%).
Profitability stack: net margin 0.0%, ROE -34.1%, ROIC -31.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +11.6%, momentum -1.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Nuvalent, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Nuvalent, Inc. Fair Value Envelope
No Revenue Data
NUVL has not reported any revenue values in the available annual periods.
Nuvalent, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
NUVL has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
NUVL has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
NUVL has not reported any net profit margin values in the available annual periods.
Nuvalent, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Nuvalent, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Nuvalent, Inc. Street Expectations Map
Wall Street analysts project that NUVL stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 177.00, with estimates ranging from a low of 165.00 to a high of 189.00.
The consensus 1-year price target stands at 177.00, with estimates ranging from a low of 165.00 to a high of 189.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Nuvalent, Inc. Insider Positioning
During the last 12 months, insiders have sold $24.78M worth of NUVL shares, with no buying activity reported.
3 Months
0
0.00
72.2K
7.19M
-7.2M
-$7.19M
3-6 Months
0
0.00
25.7K
2.80M
-2.8M
-$2.80M
6-9 Months
0
0.00
112.1K
10.23M
-10.2M
-$10.23M
9-12 Months
0
0.00
56.5K
4.57M
-4.6M
-$4.57M
Top Buyers
No buying activity
Top Sellers
Balcom Alexandra
Officer: Chief Financial Officer
$7.45M
Pelish Henry E.
Officer: Chief Scientific Officer
$6.26M
Miller Deborah Ann
Officer: Chief Legal Officer
$5.56M
Porter James Richard
Director, Officer: President And Ceo
$2.94M
Shair Matthew
Director
$1.36M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $24.78M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
NUVL has not reported any dividend yield values in the available annual periods.
nuvl Dividend History
Learning Layer
Related Guides
Build conviction on NUVL by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.